Management EfficiencyThe company has return on total asset (ROA) of (50.0) % which means that it has lost $50.0 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (421.01) % meaning that it created substantial loss on money invested by shareholders.
Entity SummaryAgenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the bodys immune system to fight cancer. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts. Agenus operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 255 people.Agenus (AGEN) is traded on BATS Exchange in USA. It is located in MASSACHUSETTS U.S.A and employs 255 people. Agenus is listed under Pharmaceutical Products category by Fama And French industry classification.
Agenus Leadership Team
Stock Performance Indicators